Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Long-Term Debt, Type [Axis]
Secured Note [Member]
Related Party [Axis]
Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Note Purchase Agreement [Member]
Investor Note 1 [Member]
Investor Note 2 [Member]
Note Purchase Agreement 2 [Member]
Legal Entity [Axis]
Ascendiant Capital Partners L L C [Member]
Note Purchase Agreement 3 [Member]
Class of Stock [Axis]
Award Type [Axis]
Warrant [Member]
Antidilutive Securities [Axis]
Options Held [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash
Prepaid expenses and other receivables
Accounts receivable - related party
Inventory
Total current assets
Property and equipment, net of accumulated depreciation
Intangible assets, net of accumulated amortization
Total other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable
Other liabilities and accrued expenses
Foreign currency contract
Due to related party
Notes payable, current portion
Deferred revenue
Total current liabilities
Notes payable, net of current portion
Deferred revenue, net of current portion
Total liabilities
Commitments and contingencies
Stockholders’ (deficit) equity:
Common stock, $0.001 par value, 42,000,000 shares authorized and 24,102,866 shares issued and outstanding at September 30, 2022 and March 31, 2022
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders’ (deficit) equity
Total liabilities and stockholders’ (deficit) equity
Common stock, par value per share
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Sales
Cost of Sales
Gross Profit
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest expense
Net loss
Other comprehensive loss:
Foreign currency translation adjustment
Comprehensive loss
Net loss per share, basic and diluted
Weighted average number of shares outstanding, basic and diluted
Statement [Table]
Statement [Line Items]
Beginning balance, value
Beginning Balance, Shares
Exercise of warrants
Exercise of warrants, shares
Foreign currency translation adjustment
Net loss
Ending balance, value
Ending Balance, Shares
Statement of Cash Flows [Abstract]
Cash Flows From Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of debt discount
Change in fair value of foreign currency contract
Changes in assets and liabilities:
Prepaid expenses and other receivables
Inventory
Accounts payable
Due to (from) related parties
Other liabilities and accrued expenses
Deferred revenue
Net cash used in operating activities
Cash Flows From Investing Activities:
Capitalized patent costs
Capitalized software development costs
Purchase of property and equipment
Net cash used in investing activities
Cash Flows From Financing Activities:
Proceeds from issuance of notes payable
Proceeds from warrant exercise
Repayments of note payable
Net cash used in financing activities
Effect of exchange rate changes on cash
Net decrease in cash
Cash at beginning of period
Cash at end of period
Supplemental disclosure of non-cash financing activities:
Release of prepayment from equity compensation
Monitoring fees added to notes payable
Accounting Policies [Abstract]
ORGANIZATION AND PRINCIPAL ACTIVITIES
BASIS OF PRESENTATION
Commitments and Contingencies Disclosure [Abstract]
LICENSING AGREEMENTS
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS
Debt Disclosure [Abstract]
NOTES PAYABLE
Equity [Abstract]
STOCKHOLDERS’ (DEFICIT) EQUITY
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER ITEMS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Basis of presentation
Use of Estimates
Cash and Cash Equivalents
Revenue Recognition
Intangible Assets
Share-Based Payments
Income Taxes
Recently adopted accounting pronouncements
Schedule of Related Party Transactions
Schedule of long term debt
Schedule of earnings (loss) per share
Accumulated deficit
Cash
Cash and cash equivalents
Non-refundable, upfront cash payment
Deferred revenue
Amounts due to related parties at beginning of period
Amounts invoiced by Pharma to DDL
Amounts invoiced by DDL to Pharma
Amounts paid by DDL to Pharma
Foreign exchange differences
Amounts due from / to related parties at end of period
2022
2023
Capital Leases, Future Minimum Payments, Receivable Thereafter
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Line Items]
Principal amount
Original issue discount
Legal fees
Commission expense
Proceeds from note payable
Monitoring fee, percentage
Agreed to pay
Commission expenses
Purchase Price
Amount paid in cash
Net loss attributable to common stockholders
Weighted average basic and diluted shares outstanding
Basic and diluted loss per share:
Schedule of Stock by Class [Table]
Class of Stock [Line Items]
Warrants exercised
Number of shares issued
Proceeds from warrants
Warrant Outstanding
Warrants to purchase
Options issued to purchase units
Anti-dilutive common stock
Subsequent Event [Table]
Subsequent Event [Line Items]
Maturity date
Notes payable
Redemption amount
Assets, Current
Other Assets, Noncurrent
Assets
Liabilities, Current
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Cost of Goods and Services Sold
Gross Profit
Operating Expenses
Operating Income (Loss)
Net Income (Loss) Attributable to Parent
Shares, Outstanding
OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Inventories
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Due from Related Parties
Increase (Decrease) in Other Accrued Liabilities
Increase (Decrease) in Deferred Revenue
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Intangible Assets
Payments to Develop Software
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Repayments of Notes Payable
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash [Default Label]
Deferred Revenue